Abstract: 16
Biomarkers are important tools for diagnosis, prognosis, and identification of the causal 17 factors of physiological conditions. Biomarkers are typically identified by correlating biological 18 measurements with the status of a condition in a sample of subjects. Cross-sectional studies 19 sample subjects at a single timepoint, while longitudinal studies follow a cohort through time. 20
Identifying biomarkers of aging is subject to unique challenges. Individuals who age faster have 21 intrinsically higher mortality rates and so are preferentially lost over time, in a phenomenon 22 known as cohort selection. In this paper, we use simulations to show that cohort selection biases 23 cross-sectional analysis away from identifying causal loci of aging, to the point where cross 24 sectional studies are less likely to identify loci that cause aging than if loci had been chosen at 25 random. We go on to show this bias can be corrected by incorporating correlates of mortality 26 identified from longitudinal studies, allowing cross sectional studies to effectively identify the 27 causal factors of aging. 28 Keywords: Regression, senescence, mortality, epigenetics, longevity, gerontology 29 30 useful for patients with untreatable cancer or Alzheimer's disease, who may wish to put their 48 affairs in order. Biomarkers for aging can similarly predict lifespan remaining or future quality 49 of life (e.g. 11). 50 Second, biomarkers can reveal disease mechanisms. Perhaps surprisingly, while glucose is 51 important to the mechanism of diabetes, historically, it did not lead physicians directly to the 52 causal mechanisms of the disease. When medieval physicians noticed that glucose in the urine 53 varied with diet, they mistakenly concluded that diabetes must be a disease of the digestive 54 system (10). Instead, the indirect advantage of the discovery of glucose was that because its 55 presence in the urine aided diagnosis, it facilitated the search for other mechanistic clues, 56 specifically abnormalities in the pancreas noted during autopsy (12) . In contrast, after cholesterol 57 was noted as a prognostic biomarker for coronary artery disease, this led more directly to 58 understanding the mechanistic role of plaque build-up (13) . 59
Third, a biomarker can provide information that enhances interventions and improves 60 outcomes (14) . Such markers are called "predictive" rather than the "prognostic" biomarkers 61 discussed above (15, 16) . Insulin treatment, combined with a more accurate blood test (17), made 62 glucose an important biomarker to drive treatment decisions (10). The presence of hormone 63 receptors in breast cancer biopsy tissue is another predictive biomarker used to make treatment 64 decisions. There is hope that the many cancer driver mutations currently being identified might 65 also move from prognostic indicators to drug targets, in the way that oncofusion protein BCR-66 Abl (18) is targeted by Gleevec. 67
Identifying biomarkers generally begins with noting a correlation between a measurement 68 and patient fate (19) (20) (21) . Patient fate can be measured longitudinally, or else a known correlate of 69 patient fate can be measured within a contemporaneous cross-section. To measure biomarkers of 70 aging in a longitudinal study, potential markers are measured at the start, and a cohort is then 71 followed through time to determine mortality. The correlation between marker status at the 72 beginning of the study and later mortality rates or other symptoms of aging is then ascertained 73 (22) (23) (24) . In a cross-sectional study, biomarkers are identified based on their ability to predict 74 either current chronological age (25), or a composite of chronological age and physiological 75 indicators often termed "biological age" (26), even when their intent, as described above, is to 76 predict lifespan remaining (27) . New technologies mean that we can now investigate many 77 potential biomarkers simultaneously, which opens the door both to discovering more and/or 78 better markers, and to the risk of spurious results (28) . 79
Longitudinal studies are obviously slow and difficult to conduct, but cross-sectional studies 80 may not yield reliable results. Individuals with lower intrinsic mortality rates are likely to survive 81 to older ages than their peers with high mortality rates, and are thereby more likely to be 82 observed at older ages. This bias, known as cohort selection (29), may complicate the search for 83 biomarkers of aging. Here, we simulate core aspects of the search for epigenetic biomarkers in 84 the cross-sectional approaches, specifically those of Horvath (25), Horvath (30) , and Levine (26) . 85
We include the possibility of cohort selection, in order to determine what cross-sectionally 86 identified biomarkers can, and cannot, tell us about aging. 87
Methods: 88
We first conduct simulations based on the procedure of Horvath (25), who trained an 89 algorithm to predict chronological age from DNA methylation status at 21,389 sites in a cross-90 section of 7,844 individuals of different ages. The resulting regression model used 353 of those 91 sites, and was used to assess the relative rate of aging (assessed as the difference between 92 predicted age and chronological age) in a wide range of test datasets, from cancer tissue to 93 patients with progeria. 94
Guided by this procedure, we simulate the methylation status of many loci during aging, 95 followed by cross-sectional approaches to select loci as biomarkers. Specifically, we simulate 96 L=20,000 loci in each individual. Each locus has two states, degraded and non-degraded, and 97 begins the simulation in the undegraded state. We simulate enough individuals to obtain 1000 98 living individuals at each target age of 10, 20, 30,…80 years, with simulations proceeding in 99 discrete time steps of one year. Each year, each un-degraded locus i has a probability " of 100 degrading, making the mean age at which the locus degrades (1i)/ i. 101
We consider two models for the probability of dying m. First, we make the probability of 102 dying increase exponentially with time, independently of which loci have degraded, according to 103 a Gompertz mortality curve (47): 104 = α exp( ) (1) 105
Using mortality rates from Arias et al. (48) , we estimate = 012 deaths/year and = 106 0.0807/year to obtain a survival curve that approximates human demography in a developed 107 nation, excluding elevated infant and early adult mortality, as well as any late life mortality 108
deceleration. 109
In the second model, we make mortality a function of the number of degraded loci, 110 choosing a function that yields a mortality curve that increases approximately exponentially with 111 age. Specifically, we make mortality a power function of the sum of the effects of all degraded 112 loci: 113
where bi is the effect size of locus i (often 0) and xi is 0 if the locus is in an undegraded state and 115 1 if the locus is degraded. Log mortality then has a linear relationship with age (i.e. we have a 116 Gompertz mortality curve) in the special case where ∑ " " = 1, with k determining its slope. 117
With < 0, mortality varies from a minimum of when no causal sites have degraded to a 118 maximum of infinity (instant death) when all sites have degraded. In our simulations, we set " 119 for all causative sites to equal 1⁄ where is the number of causative loci. We refer to the 120 "effect size" as the percent increase in mortality resulting from a single degraded locus in an 121 otherwise undegraded individual: 100 × ((1 − " ) = − 1). 122
To parameterize Equation 2 to approximate the Gompertz curve parameter values of 123 Equation (1), we assume (just for the purpose of this parameterization) that all loci degrade at the 124 same rate , and thus the expected number of degraded loci as a function of time t is E(∑ " " ) = 125
(1 − (1 − ) D ). If we ignore variation both in effect sizes of causative loci and in the number 126 of causative loci degraded, and we also ignore cohort selection (i.e. ignoring the fact that 127 individuals with more than average degradations are less likely to be alive to have their mortality 128 assessed), substitution of this expectation into Equation 2 would yield: 129
( 3) 130 We therefore set = α and = / ln(1 − ) in Equation 2. Figure 1 shows that when these 131 simplifying assumptions are relaxed, mortality in our Equation (2) simulations (red and blue for 132 small and large " , respectively) still exhibits the exponential relationship with time 133 characteristic of a Gompertz mortality curve (solid black), with a slight deviation toward late life 134 due to cohort selection when loci are of large effect (blue). 135 Some more recent efforts to identify biomarkers of aging (e.g. Levine (26)) train on a 136 measure of "biological age" that incorporates phenotypic indicators in addition to chronological 137 age. Phenotypic indicators are physiological measurements identified by their ability to predict, 138 within a linear regression, mortality rates measured in a longitudinal study. 139
To determine how including measures of biological age affects the search for causal 140 biomarkers of aging, we construct a simulated "biological age" phenotype p. We assume that 141 phenotype can be scaled such that the mean phenotype of each age group is equal to the mean 142 mortality rate of that age group (i.e., D HHHH = D J ), and that once this is done, the variance in 143 phenotype among individuals of age t is equal to the variance in mortality (i.e., vart(mi) = 144 vart(pi)). We also assume that within any age cohort, the phenotype correlates with mortality 145 with the same correlation coefficient L,N . Finally, we assume p is normally distributed, making 146 individual i's simulated phenotype: 147
where " is the true mortality rate of individual , and (0, R ) is a random number drawn from 149 a normal distribution with mean 0 and variance R . This formulation lets L,N determine the 150 fraction of variance in p that stems from variation in m, without changing vart(pi). 151
Next we consider how phenotypes can be used to construct a biological age. Simulated 152 phenotypic values could be used, along with mean mortality D HHHH for each age group, to predict 153 individual mortality rates using a linear model: 154 .
(6.1) 161
( 6.2) 163 Substituting in Equation 4 yields: 164
We next take the limit as the number of data points goes to infinity. Using 167
we obtain, after some rearrangement, 171
This reaches a minimum when the derivative by L is zero, which occurs when L = L,N . 173
To obtain an estimated biological age Yḟ from the combination of an observed phenotype 174 " and a chronological age t, using this idealized linear model, we back-transform the estimated 175 mortality from Equation 5 using the Gompertz mortality function (Equation 1): 176
For each age cohort, we simulate each individual until they either die or reach the target 178 age; only the latter are included in the training dataset. The process is repeated until we obtain 179 1000 individuals for each of the 8 ages of interest. Each locus is coded as 1 if degraded at the age 180 of sampling and 0 otherwise. We correlate loci status either with chronological age, as in 181
Horvath (25), or with biological age, as in Levine et al. (26) , using the glmnet package in R (49). 182
Regression coefficients between locus status and age are generated with a ridge lasso elastic net 183 with the elastic net mixing parameter α=0.5 as in Horvath (25). During our analysis we noticed 184 subtle biases in the regression coefficients generated by glmnet as a function of the order in 185 which the loci appear in the training data set. To prevent such biases from affecting our results, 186
we randomized the order of loci in the data set. 187
Results: 188
Here we examine the effect of two locus attributes -degradation rate, and the effect size 189 of degradation on mortality -on the regression coefficient assigned by glmnet as a predictor of 190 age. Loci with expected ages of degradation less than 40 make poor biomarkers of age, and the 191 most commonly selected biomarkers have expected ages of degradation between 60 and 100 192 ( Figure 2A) . Similarly, the most informative loci (i.e. those assigned the largest weights by 193 glmnet) are expected to degrade between ages 70 through 90 ( Figure 2B) . 194
Loci that have no causal effect on mortality are more likely to be chosen as informative 195 markers ( Figure 2C ) than their age-causing counterparts. This counter-intuitive result arises 196 because cohort selection makes biomarkers of aging unsuitable for identifying mechanisms of 197 aging. In the rare cases when age-causing loci of large effect are chosen, they have slightly 198 smaller regression coefficients than neutral loci ( Figure 2D ). Together, these results show that 199 loci that cause aging are worse predictors of chronological age than neutral loci. 200
To illustrate how cohort selection makes age-causing loci worse predictors of age, we 201 track the mean number of degraded loci as a function of cohort age. Let ni be the number of 202 individuals with i degraded loci, mi(t) the probability of dying from age t to age t+1 of 203 individuals with l degraded loci, and h"_iN ( − , − , " ) the probability from a binomial 204 distribution, of − loci degrading out of − previously non-degraded loci, when the 205 probability of a locus degrading per year is pi. The expected number of individuals of age t years 206 with l degraded loci is then: 207 k ( ) = ∑ " ( − 1)Q1 − " ( − 1)S h"_iN ( − , − , " ) k "
(4) 208
To explore the dynamics of neutral loci, we make mortality a function of time as given by 209 Equation 1 (Figure 3, dashed black) ; for causative loci, mortality is given by Equation 2 (Figure  210 3, solid grey). Early in life, the frequency of degraded age-causing loci is dominated by the rate 211 of degradation and is thus indistinguishable from neutral loci. Later in life, the additional 212 mortality incurred by age-causing loci results in a slight decline in frequency relative to non-213 causal loci. Even though cohort selection is subtle (as shown in Figure 3) , it is enough to make 214 loci that cause aging significantly worse predictors of chronological age than neutral loci. 215
Training on chronological age biases regression analysis away from identifying causative 216 loci of aging, but more recent work instead trains biomarkers on "biological age," a combination 217 of chronological age and phenotypic measurements that are known to correlate with mortality 218 (26). Such phenotypic measurements are identified by regressing phenotype and mortality over 219 the course of a longitudinal study (e.g. 23). 220
To determine if training on longitudinally validated correlates of aging can help identify 221 causative loci of aging in a cross-sectional study, we modified our analysis to incorporate 222 chronological age, a known correlate of individual mortality, and simulated noise. We construct 223 a simulated biological age-revealing phenotype such that the correlation coefficient L,N between 224 an appropriately transformed version of that phenotype and mortality has the same value within 225 each age cohort. Biological age is then calculated as an optimal function of phenotype and 226 chronological age (see Methods). When L,N R = 1, biological age perfectly reflects an 227 individual's true mortality; when L,N R = 0, it gives no information beyond that already given by 228 chronological age. Figure 4 shows that when phenotype provides little additional information 229 ( L,N R < 0.04), non-causative loci (blue circles) are preferentially chosen as biomarkers to predict 230 biological age. However, when phenotype is a reliable indicator of mortality ( L,N R > 0.7) most, 231 or even all, causative loci (red diamonds) are chosen as biomarkers of age. 232
To evaluate the quality of existing age-revealing phenotypes in the context of the search 233 for causative biomarkers of aging, we used NHANES III linked laboratory and mortality data 234 from the CDC (31, 32). We regressed (using the lm function in R) the nine phenotypic indicators 235 used in Levine et al. (26) (white blood cell count, serum alkaline phosphatase, red cell width 236 distribution, mean blood cell volume, lymphocytes percent, ln(serum C-reactive protein), serum 237 creatinine, serum albumin, and serum glucose) on lifespan remaining, including only the 6898 238 individuals who had died over the course of the study. Chronological age explained r 2 =0.184 of 239 variation in lifespan remaining, while the combination of chronological age plus phenotype 240 explained r 2 =0.28, indicating that the amount of unique information provided by phenotype is r 2 241 = 0.043 with respect to lifespan remaining, on the cusp of where biological age is useful for 242 identifying causative loci of aging in our idealized model with respect to mortality rate. 243
However, there is also considerable stochastic variation in lifespan remaining even when there is 244 no variance in underlying mortality rate. It therefore seems clear that the phenotypic age markers 245 used by Levine et al. (26) are above the threshold quality needed to identify causal loci of aging 246 more often than chance. 247
Next, we examine whether biomarkers of aging may be useful prognostic indicators of 248 variation in the overall rate of degradation between individuals. To test this, we generated 249 populations where the rate of aging varies among individuals, and populations where individuals 250 vary in initial status, but then continue to age at the same rate. We trained the model to predict 251 chronological age from loci status, as above. Comparing the difference between predicted age 252 and chronological age to the known underlying rate of aging, shows that biomarkers, even 253 neutral biomarkers, can provide useful information regarding the rate of aging ( Figure 5A ), but 254 not regarding initial mortality rate ( Figure 5B ). Note that we examined the special case in which 255 variation in either the slope or intercept of the aging curve arises at birth. These results should 256 still hold when it is later events that alter longevity, e.g. following an intervention. Biomarkers of 257 aging could therefore inform the efficacy of interventions that affect the slope of the Gompertz 258 curve, but not its intercept. 259 260
Discussion: 261
Like other biomarkers discussed in the Introduction, biomarkers of aging can have three uses: 262 to estimate lifespan remaining (prognosis), to identify the mechanisms that cause aging (33), and, 263 most ambitiously and usually late in their development, to distinguish classes of individuals for 264 whom different treatments are appropriate. In cross-sectional studies, epigenetic biomarkers of 265 aging have been selected for their ability to predict age at the time of sampling (21). However, 266 the individuals in the training dataset are not random samples from their age cohort. Specifically, 267 some individuals will not be sampled because they died before reaching the age of interest, and 268 these individuals will on average be faster-aging. The resulting bias is known as cohort selection. 269
Here, we have shown that cohort selection can make a cross-sectional study design spectacularly 270 ineffective at identifying causal factors of aging. 271
While we have focused on cohort selection associated with causal locus-induced mortality, a 272 similar sampling bias can arise from study exclusion criteria. Sicker individuals might be less 273 likely to enroll in such studies, and may be excluded, e.g. if they have defined diseases whose 274 prevalence increases with age, such as cardiovascular disease or diabetes (34). In a cross-275 sectional study, any alleles or epigenetic events that cause a predisposition toward such diseases 276 will thus be underrepresented in older individuals. 277
Even if cross-sectional analyses trained on chronological age cannot identify loci that 278 contribute to accelerating mortality, such analyses are not without value. Much effort has been 279 put into quantifying natural variation in the slope and intercept of the aging curve (35) as well as 280 the impact of interventions (36, 37) . Our simulations show that aging biomarkers can provide 281 prognostic (and hence potentially diagnostic) information regarding variation in the overall rate 282 of degradation among individuals (24), but not in the basal mortality rate. They may therefore be 283 useful in identifying factors affecting the overall rate of aging, as suggested by (25). 284
Biomarker selection enriches not just for non-causal loci, but also for loci with an expected 285 age of degradation toward the end of human lifespan. To obtain this result, we considered the 286 degradation rate of a locus to be independent of its causal effect. Whether selection against age-287 related mortality, which is necessarily subtle (38), can lead to lower degradation rates in age-288 causing loci than in the rest of the genome is an important theoretical and empirical question. 289
Degradation rates are a function of evolvable factors such as sequence context, chromatin 290 structure, or enzyme recruitment (39-41). The evolution of site-specific error rates has been 291 observed for species with larger population sizes than humans (42-44). Comparing methylation 292 changes associated with the expression of genes known a priori to play a role in aging to those in 293 putatively neutral sites may help illuminate whether loci that cause aging are under tighter 294 regulation than the genome as a whole. 295
While we have focused on molecular biomarkers of aging, our results apply to non-molecular 296 markers as well. Indeed, the most commonly used non-molecular markers of aging, such as grip 297 strength or skin elasticity (45, 46) , are non-causal. 298
Our results show that such physiological measurements, if sufficiently strongly correlated 299 with mortality, can be used to identify causal loci of aging. However, a longitudinal study is 300 required first to identify reliable physiological markers of mortality rates, whether molecular or 301 non-molecular. What we have shown is that it is possible for a cross-sectional study to "piggy 302 back" off markers identified from a longitudinal study to identify other, causative, loci of aging. 303
To better identify causal factors of aging we need a better understanding of what it means 304 to be "aged". Regression analyses using subjects' chronological ages implicitly assume that 305 "aging" is the process of having survived for a certain duration of time. Alternatively, "age" can 306 be interpreted as morbidity, with associated mortality rate following a Gompertz curve. 
